The short version of Selank fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-22. Anything still debated is marked as such rather than presented as settled.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
According to the latest systematic review of the economic literature on life satisfaction, unemployment is worse for wellbeing for those that are right wing or live in high income countries. Not all unemployment is bad, however: international data from sixteen Western countries indicates that retirement at any age yields large increases in subjective well-being that returns to trend by age 70. Executive coaching, a workplace intervention for well-being and performance, is proven to work in certain contexts, according to a 2013 independent quantitative scientific summary synthesising high quality scientific research on coaching. It tells us that standard effect sizes for the outcomes of performance/skills, well-being, coping, goal-attainment and work/career attitudes range from 0.43 to 0.74. A more recent study has challenged the Easterlin paradox. Using recent data from a broader collection of countries, a positive link was found between GDP and well-being; and there was no point at which wealthier countries' subjective well-being ceased to increase. It was concluded economic growth does indeed increase happiness. Wealth is strongly correlated with life satisfaction but the correlation between money and emotional well-being is weak. The pursuit of money may lead people to ignore leisure time and relationships, both of which may cause and contribute to happiness. The pursuit of money at the risk of jeopardizing one's personal relationships and sacrificing enjoyment from one's leisure activities seems an unwise approach to finding happiness.
== Career in industry == Between the year 1947 and 1969, Beynon was Manager of Physics and Physical, Polymer and Analytical Chemistry at Imperial Chemical Industries. Between 1947 and 1950, Beynon constructed what was to become the first mass spectrometer designed to study organic compounds unrelated to petroleum. He subsequently collaborated with Metropolitan-Vickers to produce the MS8 mass spectrometer, a prototype of the Associated Electrical Industries (AEI) MS9 mass spectrometer. Beynon was made a senior research associate in 1964 which allowed him the opportunity to carry out his own research. He was a Boomer Memorial Fellow at the University of Minnesota in 1965.
=== Production === Valve developed several VR prototypes, with three projects under development by 2017. They found the portal systems of their puzzle series Portal were disorienting in VR, but that the Half-Life systems were a natural fit. Walker said that Half-Life 3 had been a "terrifyingly daunting prospect", and the team saw VR as a way to return to the series. Additionally, they anticipated that fans would react negatively if Half-Life 3 were a VR-only game and felt a prequel carried less weight. Valve built prototypes using Half-Life 2 assets and narrowed the gameplay systems to those that best fit VR. VR affected almost every aspect of the design, including combat, level design and pacing. For example, shooting in VR, which requires the player to physically position their hand in space, is a different experience from aiming with traditional mouse-and-keyboard controls. Mike Morasky, the composer for Portal 2 and Team Fortress 2, wrote the score in consultation with Kelly Bailey, the composer for previous Half-Life games. He cited industrial music by acts such as Nine Inch Nails, the Prodigy and Skinny Puppy as inspiration. Half-Life: Alyx entered development around February 2016 and entered full production later that year. The team, comprising around 80 people, was the largest in Valve's history, and included Campo Santo, a studio Valve acquired in 2018. As Valve had repeatedly failed to see projects through, some staff were reluctant to join and many were skeptical that VR was the right direction.
Sources: en.wikipedia.org
RA reduces the size and secretion of the sebaceous glands, and by doing so reduces bacterial numbers in both the ducts and skin surface. It reduces inflammation via inhibition of chemotactic responses of monocytes and neutrophils.
==== Antigen-dependent theories ==== These theories consider a specific combination of antigen peptide sequence and the binding groove (B pocket) of HLA-B27 (which will have different properties from the other HLA-B alleles). The arthritogenic peptide hypothesis suggests that HLA-B27 has a unique ability to bind antigens from a microorganism that triggers a CD8 T-cell response that cross-reacts with a HLA-B27/self-peptide pair. HLA-B27 can bind peptides at the cell surface. The molecular mimicry hypothesis is similar, although it suggests that cross-reactivity between some bacterial antigens and self-peptides can break tolerance and lead to autoimmunity.
The breast is susceptible to numerous benign and malignant conditions. The most frequent benign conditions are puerperal mastitis, fibrocystic breast changes and mastalgia. Lactation unrelated to pregnancy is known as galactorrhea. It can be caused by certain drugs (such as antipsychotic medications), extreme physical stress, or endocrine disorders. Lactation in newborns is caused by hormones from the mother that crossed into the baby's bloodstream during pregnancy.
Sources: en.wikipedia.org
=== Depapillation === In some diseases, there can be depapillation of the tongue, where the lingual papillae are lost, leaving a smooth, red and possibly sore area. Examples of depapillating oral conditions include geographic tongue, median rhomboid glossitis and other types of glossitis. The term glossitis, particularly atrophic glossitis is often used synonymously with depapillation. Where the entire dorsal surface of the tongue has lost its papillae, this is sometimes termed "bald tongue". Nutritional deficiencies of iron, folic acid, and B vitamins may cause depapillation of the tongue.
It was suggested by Nichols as a more economical and accessible alternative to psilocybin for use in scientific research, as the synthesis of psilocybin is more challenging and as psilocybin is a controlled substance. 4-AcO-DMT was first detected as a designer drug in Europe in 2009. It became increasingly prevalent as a recreational drug in the 2010s and has been the most commonly used novel tryptamine. In the 2020s, 4-AcO-DMT became widely encountered in the form of mushroom edibles in the United States as an alternative to psilocybin. Relatedly, it has sometimes been referred to as "synthetic shrooms". So-called "mushroom edibles" sold at places such as gas stations and headshops may contain 4-AcO-DMT, Amanita muscaria mushroom extract, or unrelated drugs such as bath salts, and have been linked to severe and potentially deadly adverse effects. 4-AcO-DMT is not scheduled under United States law or any international drug schedules, including the United Nations 1971 Convention on Psychotropic Substances, making it a potentially more accessible alternative to psilocybin for research. It can be imported and possessed for research in the United States if labeled "for research purposes only not approved by the FDA for human consumption,", however marketing or distributing it to humans as psilocybin, a schedule 1 narcotic carries the same penalties of intent.
Operational Detachments "Alpha" deployed to Haiti to conduct Coalition Support Team missions in 1993–94 in support of U.S. Joint Task Force 190 and Multi-National Force operations supporting Operation Uphold Democracy. Additional ODAs conducted Humanitarian Demining Operations in Laos, Thailand, Cambodia, and Vietnam earning Humanitarian Service Medals for their efforts in both Laos and Thailand. Elements from the 1st SFG (A) conducted training with military units from newly created states from the former Soviet Union that supported the development of the Central Asian Battalion (CENTRASBAT), a regional peace-keeping force in the mid-1990s. By the end of the millennium, 1st SFG (A) soldiers had deployed for the Stabilization Force in Bosnia-Herzegovina. Following the 11 September attacks, members of the 1st SFG (A) deployed to support Operation Enduring Freedom in Afghanistan and sustained back-to-back battalion rotations to the Philippines. Starting in February 2002, elements of the 1st SFG (A) deployed to conduct unconventional warfare in the Southern Philippines by and with the Armed Forces of the Philippines (AFP) in order to assist the Government of the Philippines (GOP).
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.